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Introduction
Prostate cancer is the most common malignancy in 
men (1). Patients with localized prostate cancer have 
multiple treatment options including active surveillance, 
prostatectomy, brachytherapy, and external beam radiation 
therapy (EBRT). A patient’s preference toward a specific 
treatment is often driven by the invasiveness of the 
treatment modality and the expected side effects from that 
particular intervention. EBRT, considered as one of the 
least invasive treatments, has changed drastically over the 
past several decades with the ultimate goal of improving 
survival outcomes with decreasing toxicity. Older techniques 
were replaced with 3-dimensional (3D) conformal radiation 
therapy (CRT), and further technological advancements 
in radiation imaging, planning, and delivery has allowed 
the introduction and wide adoption of intensity-modulated 
radiation therapy (IMRT). IMRT uses 3D imaging to guide 
beams of radiation to the tumor from many different angles 
while changing (modulating) the intensity and shape of the 
beam to match the shape of the tumor. These adjustments 
of the radiation allow for the prescribed amount of radiation 
to be delivered to each part of the tumor while minimizing 
the amount of radiation normal surrounding healthy tissue 
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receives. For prostate cancer, multiple randomized and 
nonrandomized series have shown improved tumor control 
with the use of dose escalated therapy (2-7). The enhanced 
conformality of IMRT allow for dose escalation to the 
prostate while reducing dose to the bladder and rectum, 
and trials have demonstrated reduced toxicity with IMRT 
(8,9). In addition to the fundamental principles of the 
IMRT technique, there are numerous biologic, anatomic, 
and clinical features which also make prostate cancer a 
model site for implementation of IMRT. In this review, 
we describe the evolution of EBRT to IMRT, describe the 
specific features of prostate cancer which make this disease 
an ideal site for implementation and routine use of IMRT, 
comparisons between IMRT and 3D-CRT including 
genitourinary (GU) and gastrointestinal (GI) toxicities, 
clinical outcomes of IMRT including dose escalation, and 
future directions utilizing this technology.  
Evolution of external beam radiation to IMRT
Historically, definitive radiation for prostate cancer was 
accomplished using 2-dimensional (2D) or 3D-CRT. The 
most common conventional beam arrangement was a “four 
field box” arrangement consisting of a pair of anterior-
posterior and posterior-anterior (AP-PA) beams, as well as a 
pair of lateral opposed beams. This approach was commonly 
used into the early 1990s, until 3D-CRT became more 
widely adopted. 3D-CRT takes advantage of sophisticated 
computer software, and included computed tomography 
(CT) simulation to integrate volumetric data regarding the 
patient’s tumor and organs at risk to allow for beam angles 
and radiation portals that were difficult to implement using 
conventional 2-dimensional planning.
Dearnaley et al. conducted a randomized study of 
conventional vs. 3D-CRT to a dose of 64 Gy in 2 Gy 
fractions, which at that time was a standard dose for 
prostate cancer (10). Of the 225 men treated, significantly 
fewer men developed radiation proctitis and bleeding in the 
3D-CRT group compared to the conventional group (5% 
vs. 15% grade 2+) and there was no difference in tumor 
control. As toxicity was reduced with 3D-CRT, several 
groups conducted studies to escalate the radiation dose 
to the prostate tumor. The outcomes of dose escalation 
with 3D-CRT have been summarized in several other 
review articles (11-14). In general, they observed that 
the radiation dose could be escalated from the range of 
64–68 Gy to the range of 74–81 Gy using 3D-CRT, and 
resulted in improved biochemical progression free survival 
rates. These results are summarized by a meta-analysis 
conducted by Viani et al., which pooled seven randomized 
trials with a total patient population of 2,812 (15). They 
identified that dose-escalated radiation resulted in 
significant reductions in biochemical failure, but there were 
no differences in the rate of all-cause or prostate cancer 
specific mortality. Furthermore, there were also more cases 
of late grade 2+ GI toxicity in the high-dose radiation 
groups, with the absolute difference typically ranging 
between 5–10% between the study arms.
In particular, the Radiation Therapy Oncology Group 
(RTOG) conducted protocol 9406 which used 3D-CRT 
to sequentially increase the radiation dose to several 
levels including 68.4 (1.8 Gy per fraction), 73.8 (1.8 Gy 
per fraction), 79.2 (1.8 Gy per fraction), 74.0 (2.0 Gy per 
fraction), and 78.0 (2.0 Gy per fraction) (16). These regimens 
resulted in disease free and biochemical progression free 
survival rates which compared favorably with historical data. 
Additionally, the toxicity results with 3D-CRT, including 
the maximum dose levels of 79.2 Gy in 1.8 Gy per fraction 
and 78.0 Gy in 2.0 Gy per fraction were low compared 
to historical controls (17). However, the 78 Gy in 2.0 Gy 
fractions dose level was ultimately associated with a greater 
incidence of late grade 2+ toxicity compared to 79.2 Gy 
in 1.8 Gy per fraction (30–33% vs. 9–13%). These results 
established a dose of 79.2 Gy in 1.8 Gy fractions for prostate 
cancer that is commonly used at Washington University in 
St. Louis.
An additional refinement on 3D-CRT is a technique 
known as IMRT. IMRT uses beam modulation and “field 
in field” techniques made possible by multi-leaf collimators 
combined with sophisticated inverse planning software. The 
IMRT approach allows the radiation oncologist to prescribe 
doses to target structures such as the prostate and proximal 
seminal vesicles and dose constraints to nearby normal 
structures such as the rectum and bladder. The computer 
software then determines the beam modulation to optimally 
achieve the radiation prescription. The resulting radiation 
distribution appears “sculpted” to cover the target and to 
avoid normal structures in a way that would typically not be 
achievable using conventional planning methods as seen in 
Figure 1. Although the mathematics underlying IMRT were 
published in the late 1980s and early 1990s, clinical IMRT 
systems were not implemented until the mid to late 1990s 
and commercial systems were not in common use until the 
early 2000s.
There are no randomized controlled trials directly 
comparing dose escalated IMRT and 3D-CRT in prostate 
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cancer. However, several single institution retrospective 
studies have demonstrated improved biochemical control 
and/or reduced GI toxicity with IMRT as compared 
to 3D-CRT (18-20). Additionally, in RTOG 0126, a 
randomized study of dose escalation in intermediate risk 
prostate cancer, a reduction in late grade 2+ GI toxicity 
of 15% vs. 22% was observed with IMRT compared to 
3D-CRT in the 79.2 Gy high dose arm (8). These studies 
will be discussed in detail later in this review.
 The reduction in toxicity of IMRT as compared to 
3D-CRT has led to its rapid adoption in the United 
States. In a SEER-Medicare study, IMRT use increased 
substantially as a proportion of patients treated with 
radiation from 28% in 2002 to 82% in 2005 (21). According 
to the most recent 2016 American College of Radiology 
Appropriateness Criteria, the use of 3D-CRT for dose 
escalated treatment of prostate cancer is typically no 
longer appropriate if other options, such as IMRT, are 
available (22).
Anatomic and biologic features which make 
prostate cancer a model site for implementation 
of IMRT
The prostate is located in close proximity to the rectum, 
bladder, penile bulb, and femoral heads which are at risk 
of receiving radiation dose and subsequent toxicity due 
to prostate cancer treatment. IMRT has been shown in 
dosimetric studies to substantially decrease the amount of 
unintentional radiation delivered to these normal structures. 
In RTOG 0126, a comparison of the dosimetry of IMRT 
and 3D-CRT plans in the 79.2 Gy arm showed that the 
percent of the rectum treated to at least 75 Gy (rectum 
V75) was reduced from 15.8% to 13.0%, and the V65 was 
reduced from 27.4% to 23.0% (8). The bladder V75 was 
reduced from 17.7% to 13.1% and the V65 was reduced 
from 25.3% to 19.7%. A dosimetric study by Hardcastle 
et al. showed similar findings suggesting a reduction in the 
rectum V75 from 23.2% to 9.9%, resulting in an estimated 
reduction in rectal complication rates from 14% to 
5% (23). Luxton et al. have estimated that the mean dose 
to the femoral heads can be approximately halved by 
using IMRT over 3D-CRT (24). Additional studies have 
shown the possibility of IMRT in reducing radiation dose 
to the penile bulb (mean dose 33 vs. 49 Gy for IMRT vs. 
3D-CRT) (25) The normal structure dose constraints used 
for IMRT plan optimization used at Washington University 
in St. Louis are listed in Table 1. The ability of IMRT to 
reduce dose to nearby normal structures without sacrificing 
dose coverage of the target makes it an ideal treatment 
modality for prostate cancer. 
Figure 1 Illustrative IMRT plan treating the prostate and proximal 
seminal vesicles. The images show the radiation dose distribution 
in the axial (top center), coronal (bottom left), and sagittal (bottom 
right) orientations. The dose color-wash shows the radiation 
dose distribution as percentage of the prescription dose. Regions 
outside of the color-wash received less than 20% of the radiation 
prescription dose. The treatment plan encompasses the prostate 
(red structure) and proximal seminal vesicles (green structure) and 
avoids nearby regions such as the bladder, rectum, penile bulb, and 
femoral heads. The dense structures inside the prostate are fiducial 
markers placed for image guidance. The radiation plan includes 
seven beam angles and uses beam energy of 10 mega-volts (MV). 
IMRT, intensity-modulated radiation therapy.
Table 1 Target and normal structure constraints used for prostate 
IMRT optimization at Washington University in St. Louis. For 
example, the interpretation of the constraint “Rectum V65 Gy 
<17%” can be explained as: limit volume of rectum receiving  
65 Gy or greater to less than 17 percent of the total volume of the 
structure
Structure Optimization parameter
Planning target volume 
(PTV)
Cover 98% of PTV with 100% of 
prescription dose
Rectum V65 Gy <17% and V40 Gy <35%
Bladder V65 Gy <25% and V40 Gy <50%
Femoral heads V50 Gy <10% for each femoral head
Penile bulb Mean dose <52 Gy
IMRT, intensity-modulated radiation therapy.
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There may be additional radiobiological considerations 
that make prostate cancer a good target for IMRT, 
due to the alpha/beta ratio of the tumor and the use of 
hypofractionated radiation treatments. The response 
of tumor cells and normal tissue to therapeutic doses of 
radiation can be characterized by the alpha/beta ratio 
(α/β). This radiobiologic parameter is useful in determining 
the effect of various dose and fractionation schemes on 
the tissue. In this model, α represents the cells that die 
after one “hit” of radiation and β represents the cells that 
die after two “hits”, representing the ability to repair 
sublethal damage. The ratio of these two parameters, α/β, 
represents the “sensitivity” of a tissue to radiation. Rapidly 
proliferating cells, such as most tumors, are characterized 
by a α/β of ≥10 whereas most normal tissues, which are 
comprised of slower proliferating cells, have an α/β of 2–3. 
Tissues with low α/β are thought to be more sensitive to 
radiation given in large doses per treatment (large fraction 
sizes), while tissues with high α/β are thought to be more 
responsive to smaller fraction sizes. The combination of 
α/β ratio, dose per fraction, and number of fractions in 
a radiation treatment course can be used to calculate the 
biologically effective dose (BED), which is a measure of 
damage to tumor cells that can be calculated from many 
different radiation regimens.
Surprisingly, while most tumors have high α/β values, 
radiobiological models based on clinical data suggest that 
prostate cancer has a low α/β ratio of about 1.5 Gy, which is 
actually lower than that of many normal tissues in the pelvis 
(26,27). This finding implies that although dose escalation 
using conventional fractionation (1.8–2.0 Gy per fraction) 
has been effective for prostate cancer, an alternative 
method of improving the therapeutic ratio may include 
hypofractionation, the use of doses >2.0 Gy per radiation 
treatment (28). 
The efficacy and toxicity of moderate hypofractionation 
has been tested in several studies (29). The United Kingdom 
CHHiP study randomized patients to 74 Gy in 2 Gy 
fractions vs. two hypofractionated regimens of 60 Gy in 20 
fractions or 57 Gy in 19 fractions (29). IMRT was mandated 
in this study, and there were no differences in toxicity or 
cancer-related outcomes (29,30). The RTOG conducted 
a randomized study comparing a dose of 73.8 Gy in 
1.8 Gy fractions to moderate hypofractionation to a dose of 
70 Gy in 28 fractions (31). This study of 1,092 men with low 
risk prostate cancer established that the hypofractionated 
regimen was non-inferior in efficacy compared to the 
conventional regimen (31). However, there was an increase 
in late GI/GU adverse events with hypofractionated 
treatment. Both 3D-CRT and IMRT was allowed on 
this study. The Dutch HYPRO study also randomized 
patients between a conventional and hypofractionated dose 
regimen, and there was a ~95% utilization of IMRT in both 
arms (32). The late toxicity results of this study showed 
that the incidence of grade 3+ GI toxicity between the two 
regimens were not different (2.6% vs. 3.3%), but the late 
grade 3+ GU toxicity was not non-inferior between the 
conventional and hypofractionated treatments (13% and 
19% respectively) (32). Five-year rates of treatment failure 
and relapse free survival were not significantly different 
between the two groups (32).
Although further analysis and reporting of the data is 
needed, the evidence above may suggest that IMRT is 
important to the delivery of moderate hypofractionation 
without excess GI toxicity. However, the ability of IMRT 
to reduce GU toxicity is limited as a portion of the bladder 
and prostatic urethra are necessarily within the treatment 
volume. Future studies will better define the appropriate 
tissue constraints to use for hypofractionated radiation, and 
the full benefit of IMRT in this setting.
Technical aspects of IMRT
IMRT combines inverse treatment planning and computer-
controlled intensity modulation of the radiation to 
deliver 3D-CRT. Since the introduction of IMRT, many 
techniques for IMRT treatment of the prostate have been 
implemented (33). A common approach is the use of 
multiple coplanar fields arranged at equal or nearly equal 
spacing around the patient (33). Usually between 5 to 9 
static fields are used for this approach, and in general, dose 
homogeneity and conformality improve as the number of 
treatment fields increases, however the benefit with field 
numbers beyond 7 to 9 diminishes (33,34). Noncoplanar 
beam arrangements, volumetric-modulated arc therapy 
(VMAT) and tomotherapy have been developed in attempts 
to further improve the dose distribution and are commonly 
used at many institutions. 
IMRT treatment plans are designed by using specialized 
computer algorithms commonly termed “inverse treatment 
planning and optimization” systems (33). The user 
selects objectives, usually termed constraints and goals, 
that describe the desired dose to each target and organ 
at risk, and penalties are assigned based on the relative 
importance of each objective (33). These constraints 
and penalties are then combined into the mathematical 
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algorithm according to a cost function and the intensity of 
beamlets within each field are adjusted iteratively until the 
cost function is minimized and thereby determining the 
intensity of each beam that leads to the closest profile as 
stated in the objective goals (33). Optimization objectives 
are both planning system and patient specific, therefore 
many institutions have developed institutional constraint 
templates that are used as a starting point for the planning 
process (33). The delivery of IMRT is than achieved by using 
either sequential delivery of multiple static apertures from a 
multileaf collimator (MLC) termed “step and shoot”, or as 
dynamic multileaf movement termed “sliding window” (35). 
Other techniques for delivery are available, but these two 
methods remain the most common.  
After an acceptable IMRT plan has been generated, it 
is important to ensure the plan is properly implemented. 
Delivery of the complex intensity profiles created 
during the IMRT optimization process is performed by 
sophisticated mechanical and computerized delivery systems 
on a linear accelerator. Quality assurance is an integral part 
of this process and is typically performed with dosimetric 
verification of the leaf motion and sequencing for each 
field as well as computer based verification of the dose 
distribution and monitor unit settings for each field. 
Outcomes with IMRT
Evidence from several single institution studies and 
multiple randomized control trials demonstrate a dose-
response relationship with doses above 68 Gy associated 
with improved local and biochemical control (4,7,36). A 
summary of randomized dose escalation trials is found in 
Table 2. Additionally, dose-volume toxicity relationships 
have also been established for rectal bleeding and other GI 
and GU toxicities with increased high dose associated with 
increased risk of toxicity (4,37-40). IMRT is a method to 
escalate dose while achieving safe dose-volume constraints 
to organs at risk. 
Published in 2007, Vora et al. evaluated biochemical 
control rates and prognostic factors for patients with 
localized prostate cancer treated with either high-dose 
IMRT or conventional-dose 3D-CRT. A total of 271 
patients received 3D-CRT with a median dose of 68.4 Gy 
(range, 66.0–71.0 Gy), and 145 patients received IMRT 
with a median dose of 75.6 Gy (range, 70.2–77.4 Gy). Using 
the ASTRO Phoenix definition, the 5-year biochemical 
control rate was 74.4% for 3D-CRT and 84.6% with IMRT 
(P=0.033). On both univariate and multivariate analysis, 
increased dose was associated with improved biochemical 
control (19).
Despite improvements in prostate RT and increased 
dose conformity, rectal complications have not been 
eliminated and rectal toxicity remains a major concern for 
men undergoing EBRT. Giordano et al. (41) performed 
a population based analysis using the SEER database to 
determine the rates and predictors of late lower GI toxicity 
after prostate radiation prior to the IMRT era. They 
compared a group of men with prostate cancer treated with 
EBRT (n=24,130) compared to those treated without RT 
(n=33,835) from 1992 to 1999. For patients with a minimum 
of 5 years follow-up, the rates of GI diagnoses were 19.4% 
higher in the radiation group (41). Hemorrhage was the 
most common complication, and was increased by 19% 
for patients treated with radiation (39.6% of RT patients 
vs. comparison rates of 18.2% in patients treated with 
radical prostatectomy and 20.7% in patients with no local 
therapy) (41). Several single institutional series have 
reported a reduction in late toxicity since the introduction 
of IMRT as compared to conventional RT.
Jani et al. reviewed the records of 461 patients with 
localized prostate who received either IMRT (n=106) or 
conventional RT defined as 4- or 6-field conformal therapy 
Table 2 Randomized trials evaluating external beam radiation therapy dose escalation for localized prostate cancer
Study Patients Dose (Gy) Median follow-up (months) bDFS Grade 2+ GI toxicity
MD Anderson 301 78 vs. 70 104 78% vs. 59%* 26% vs. 13%*
PROG 95-09 393 79.2 vs. 70.2 107 83% vs. 68%* 24% vs. 13%
MRC RT01 843 74 vs. 64 120 55% vs. 43%* 33% vs. 24%*
GETUG 06 306 80 vs. 70 61 72% vs. 61%* 20% vs. 14%
Dutch CKVO96-10 669 78 vs. 68 70 54% vs. 47%* 35% vs. 25%*
*, P<0.05. bDFS, biochemical disease-free survival; GI, gastrointestinal.
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(n=355) from 1998 to 2005 (42). Late GI toxicities were 
found to be lower with IMRT (P<0.001) and regression 
analyses demonstrated that IMRT was the only factor 
predictive of late GI toxicity. On analysis of the DVH data, 
it was hypothesized that the GI toxicity rates were lower 
for the IMRT group due to lower mid-to-high range rectal 
dosimetric metrics (V40, V50, V60, and V70). There was 
no association of decreased GU complications with IMRT 
compared to conventional treatment (42). 
Sanguineti et al. compared the late rectal toxicity rates 
after 3D-CRT to the prostate alone and whole-pelvis IMRT 
along with a prostate boost to the same nominal total dose 
to the prostate in both groups (43). Sixty-eight patients 
were treated to the prostate alone using 3D-CRT to a total 
dose of 76 Gy. A second group of patients consisted of 
45 patients treated with IMRT covering the pelvic lymph 
nodes and seminal vesicles to 54 Gy in 1.8 Gy fractions and 
the prostate to 60 Gy in the same 30 fractions followed by 
a boost to the prostate alone to 76 Gy (43). Planning was 
similar for both groups, with both receiving 76 Gy to the 
prostate, with the main difference being the inclusion of the 
pelvic lymph nodes in the IMRT group (43). Late toxicity 
was prospectively scored using the RTOG scale and all 
patients had a minimum of 12 months follow-up. At 2-years, 
the cumulative incidence of grade 2 late rectal toxicity was 
greater for the group receiving 3D-CRT (21.2%±6%) 
compared to IMRT (6%±4%) despite the IMRT group 
receiving treatment to the pelvic lymph nodes. On 
multivariate analysis the difference was statistically in favor 
of IMRT [hazard ratio (HR): 0.1; 95% CI, 0.0–0.6; P=0.01]. 
No patients in either group developed grade 3+ toxicity (43). 
Wortel et al. analyzed the late side effects after treatment 
with image-guided (IG)-IMRT or 3D-CRT, evaluating 
2 prospective cohorts of men treated with localized 
prostate cancer to investigate hypothesized reductions in 
toxicity (44). Patients from two Dutch randomized trials 
were treated with 3D-CRT (n=189) or IG-IMRT (n=242) to 
78 Gy in 39 fractions with identical toxicity scoring 
protocols (modified RTOG-EORTC scoring criteria). 
The 5-year cumulative incidence of grade ≥2 GI toxicity 
was 24.9% for IG-IMRT and 37.6% following 3D-CRT 
(adjusted HR: 0.59, P=0.005). There was significant 
reduction in proctitis (HR: 0.37, P=0.047) and increased 
stool frequency (HR: 0.23, P<0.001). GU grade ≥2 toxicity 
remained comparable between the two groups. Other 
predictors of late grade ≥2 complications were baseline 
complaints, acute toxicity, and age (44).
The RTOG 0126 was a prospective randomized phase 
III trial comparing escalated high dose RT to conventional 
dose RT for localized early stage intermediate risk 
prostate cancer which opened in March 2002 and closed 
to accrual in 2008. The primary endpoint of the study 
was to determine whether 3D-CRT or IMRT to 79.2 Gy 
in 44 fractions would lead to improved overall survival in 
patients with intermediate risk prostate cancer compared 
to those patients treated with the same techniques to 
70.2 Gy in 39 fractions. The protocol initially included 
only 3D-CRT, however, in September 2003 the trial was 
amended to allow IMRT, and treatment modality was added 
as a stratification variable in order to help avoid treatment 
arm modality imbalances. Of the 1,532 patients enrolled on 
the trial, 763 were randomized to the high dose treatment 
arm. In this arm, patients treated with 3D-CRT received 
55.8 Gy to a planning target volume that included the 
prostate and seminal vesicles, and then a 23.4 Gy boost to 
the prostate alone. Patients receiving IMRT were treated 
to the prostate and seminal vesicles to 79.2 Gy. In 2013, 
a preliminary toxicity analysis of 3D-CRT versus IMRT 
was published reporting acute and late effects between the 
two techniques (8). 748 of the 763 patients were eligible 
of whom 491 received 3D-CRT and 257 received IMRT. 
After dosimetric analysis, the median % of the bladder 
receiving at least xGy (pVx equals partial volume receiving 
‘x’ Gray) for pV65, pV70 and pV75 were 25.3%, 22.2%, 
and 17.7% for 3D-CRT and 19.7%, 16.6% and 13.1% for 
IMRT. The median rectum pV65, pV70 and pV75 were 
27.4%, 21.7%, and 15.8% for 3D-CRT and 23.0%, 18.2% 
and 13.0% for IMRT. For both the bladder and rectum, 
the volumes receiving 65, 70, and 75 Gy were significantly 
lower in the IMRT cohort (all P<0.0001). For grade 2+ 
acute GI/GU toxicity, both univariate and multivariate 
analyses showed a significant decrease in collective GI/
GU toxicities in favor of IMRT. There was no significant 
difference between 3D-CRT or IMRT for acute or late 
grade 2+ or 3+ GU toxicities. Univariate analysis indicated a 
statistically significant decrease in late grade 2+ GI toxicity 
for IMRT (P=0.039). In multivariate analysis, IMRT had 
a 26% reduction in late grade 2+ GI toxicity compared 
to 3D-CRT (P=0.099). Additionally, small volumes of 
the rectum exceeding high threshold radiation doses (i.e., 
>70 Gy) were associated with nearly a two-fold risk of late 
grade 2 or greater toxicity. If more than 10% or 15% of the 
rectum volume exceeded 75 or 70 Gy, respectively, patients 
had a significantly greater risk of late GI toxicity. After both 
modality and the dose thresholds were included in the GI 
toxicity analysis, there was still a separation between the 3D 
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and IMRT arms at each dose constraint level with a larger, 
however not statistically significant, separation for the 
>10% dose constraint groups. Based on these preliminary 
findings of RTOG 0126, IMRT is associated with a 
significant reduction in acute grade 2+ GI/GU toxicity and 
there is a trend for a clinically meaningful reduction in late 
grade 2+ GI toxicity with IMRT. The occurrence of acute 
GI toxicity and large (>15%) volumes of rectum >70 Gy are 
associated with late rectal toxicity. The final results of this 
trial are pending publication this year. 
In September 2017, a national population based study 
was performed comparing treatment-related toxicity in 
men who received IMRT versus 3D-CRT for prostate 
cancer (45). Patients treated for prostate cancer between 
January 2010 and December 2013 in the English National 
Health Service were included (N=23,222). A total of 16,289 
patients treated with 3D-CRT and 6,933 patients with 
IMRT. Patients with severe toxicity, defined as at least grade 
3 according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events scoring system 
were identified. A competing risks regression analysis was 
used to estimate HRs, comparing the incidence of severe GI 
and GU complications after IMRT and 3D-CRT, adjusting 
for patient, disease, and treatment characteristics. The use 
of IMRT, as opposed to 3D-CRT, increased from 3.1% in 
2010 to 64.7% in 2013 in this cohort. Patients who received 
IMRT were less likely than those receiving 3D-CRT to 
experience severe GI toxicity [4.9 vs. 6.5 per 100 person-
years; adjusted HR: 0.66; 95% confidence interval (CI), 
0.61–0.72]. Similar rates of GU toxicity were observed (2.3 
vs. 2.4 per 100 person-years; adjusted HR: 0.94; 95% CI, 
0.84–1.06) (45).
Lastly, a meta-analysis of 23 studies (n=9,556) comparing 
the clinical outcomes, including GI toxicity, GU toxicity, 
biochemical control and overall survival was performed (46). 
IMRT was significantly associated with decreased grade 
2–4 acute GI toxicity (risk ratio =0.59 (95% CI, 0.44–0.78), 
late GI toxicity (risk ratio =0.54, 95% CI, 0.38–0.78), late 
rectal bleeding (risk ratio =0.48, 95% CI, 0.27–0.85), and 
achieved better bio-chemical control (risk ratio =1.17, 95% 
CI, 1.08–1.27) in comparison with 3D-CRT (46). IMRT 
and 3D-CRT remained the same in regard to grade 2–4 
acute rectal toxicity (risk ratio =1.03, 95% CI, 0.45–2.36), 
late GU toxicity (risk ratio =1.03, 95% CI, 0.82–1.30) and 
overall survival (risk ratio =1.07, 95% CI, 0.96–1.19), while 
IMRT slightly increased the morbidity of grade 2–4 acute 
GU toxicity (risk ratio =1.08, 95% CI, 1.00–1.17) (46).
IMRT for pelvic lymph node radiation
A subset of patients with prostate cancer, typically those 
with high risk disease, may benefit from radiation to 
the pelvic lymph nodes in addition to the prostate and 
proximal seminal vesicles. In these situations, the use of 
IMRT might also be beneficial in reducing toxicity in 
comparison to 3D-CRT. Although no randomized study 
has been conducted in prostate cancer comparing 3D-CRT 
and IMRT techniques in treating the pelvic lymph nodes, 
some insight can be gained from extrapolating from other 
disease sites in which pelvic nodal coverage is indicated. 
For instance, the multi-national TIME-C study enrolled 
278 patients with endometrial or cervical cancer and 
randomized the patients after surgery to IMRT or four-
field pelvic radiation treatment and evaluated patients 
using the Expanded Prostate Cancer Index Composite 
(EPIC) (47). A preliminary presentation of the toxicity 
outcomes at ASTRO in 2016 suggested that IMRT reduced 
GI toxicity including diarrhea and fecal incontinence 
compared to 3D-CRT (47). Patients receiving IMRT 
also had smaller declines in EPIC urinary domain scores. 
Limitations in extrapolating data from this study to 
patients with prostate cancer includes the fact that patients 
in TIME-C received prior surgery, a subset received 
concurrent chemotherapy, and the volumes treated with 
radiation for gynecological tumors may differ from that for 
prostate cancer. 
Additional insight on IMRT to the pelvic volume 
may be gained by examining retrospective and single 
arm prospective studies in prostate cancer. A dosimetric 
study by Guckenberger et al. compared the risk of toxicity 
using normal tissue complication probability (NTCP) 
calculations after IMRT to the prostate only compared to 
additional irradiation of the pelvic lymphatic region in a 
retrospective cohort of 10 patients (48). They concluded 
from this planning study that the NTCP model predicted 
similar risks of rectal (5–8%) and bladder (1%) toxicity 
after prostate-only or prostate and pelvis IMRT. However 
the risk of toxicity to the small bowel was estimated to be 
increased with inclusion of the pelvic volume IMRT to 
0.8–3.2%. Deville et al. retrospectively compared patients 
treated with dose-escalated IMRT to 79.2 Gy to the 
prostate alone or also with 45 Gy by IMRT to the pelvis (49). 
Although the acute grade 2+ GI toxicity was greater with 
the inclusion of pelvic radiation (50% vs. 13%), there was 
no difference in late GI or GU toxicity with the addition of 
pelvic IMRT (49). These estimated risks are also similar to 
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the observed toxicity reported in a phase 1–2 study of dose-
escalated IMRT to the prostate and pelvic nodes reported 
by Reis Ferreira et al. (50). They enrolled 447 patients with 
locally advanced prostate cancer and treated with IMRT 
of 70–74 Gy to the prostate and dose escalated IMRT to 
the pelvic lymph nodes to 50–60 Gy. The 2-year rates of 
grade 2+ bowel and bladder toxicity in patients receiving 
conventionally fractionated pelvic IMRT ranged from 
8.3–13.2% and 2.9–5.9% respectively. The importance of 
reducing toxicity is especially important as it is becoming 
recognized that larger radiation fields such as those 
extending to L4/L5 may be necessary to adequately cover 
the lymph node regions commonly involved with prostate 
cancer metastasis (51).
In the setting of modern dose escalation and androgen 
depravation therapy, the benefit of pelvic nodal irradiation 
in patients with unfavorable intermediate risk and high risk 
prostate cancer is still debatable. RTOG 0924 is an ongoing 
study investigating the benefit of pelvic radiation in addition 
to ADT and prostate dose escalation (52). Although both 
3D-CRT and IMRT is allowed for the pelvic field, it is 
expected that most of the patients will be treated with 
IMRT. Outcomes and toxicity data from this randomized 
study will better define the benefit and risks of covering the 
nodal regions with IMRT in prostate cancer.
Future directions
As described above, clinical studies suggest that prostate 
cancer has biologic characteristics which may make 
it more sensitive to larger doses per fraction (i.e., 
hypofractionation) (27,53). These higher doses per fraction 
may lead to better tumor kill compared to conventional 
fractionation while offering increased patient convenience 
from a shorter course of treatment and also fewer burdens 
on the health care system with decreased treatment costs. 
The CHHiP trial (a randomized, phase 3, non-inferiority 
trial) demonstrated that hypofractionated radiotherapy 
with IMRT using 60 Gy in 20 fractions is non-inferior to 
conventional fractionation using 74 Gy in 37 fractions and 
is recommended as a new standard of care for external-
beam radiotherapy of localized prostate cancer (54). 
Further hypofractionation, specifically stereotactic body 
radiation therapy (SBRT) which uses even larger doses per 
fraction, are currently under investigation. RTOG 0938 is 
a randomized phase II trial of hypofractionated radiation 
therapy for favorable risk prostate cancer in which patients 
are assigned to either 36.25 Gy in 5 fractions (7.25 Gy 
per fraction) versus 51.6 Gy in 12 fractions (4.3 Gy per 
fraction) (55). This protocol requires the use of IMRT 
or related technologies (i.e., Tomotherapy/VMAT/
Cyberknife and proton therapy) given the large doses per 
fraction and risk to healthy pelvic organs (55). 
Additional methods to improve the toxicity profile of 
IMRT for prostate cancer are the use of a hydrogel spacer. 
Given that the prostate and rectum are often in immediate 
physical contact, even the most conformal IMRT plan 
cannot always spare high dose radiation being delivered to 
the rectum. An absorbable hydrogel injected between the 
prostate and rectum has been shown in a randomized trial 
to have a clinically significant 25% reduction in the rectal 
V70 Gy in >97% of men, correlating with a reduction in 
rectal toxicity, improvement in bowel quality of life, and 
improved sexual function (56-59). 
Conclusions 
Radiation therapy for prostate cancer has evolved 
dramatically over the past 2 decades. Treatment has 
evolved from X-ray fields based on bony anatomy to dose 
escalated radiation therapy with image-guidance and 
IMRT. Published dose-volume constraints that can reduce 
or prevent rectal injury have been established and are 
achievable with IMRT. Multiple randomized, retrospective, 
and population based studies have shown that men who 
receive radiation therapy using IMRT were less likely to 
experience severe GI toxicity compared with those who 
received 3D-CRT. The radiobiology of prostate cancer also 
suggests it may be more responsive to hypofractionated 
treatment, and IMRT is a method to deliver higher doses 
per fraction while minimizing dose to organs at risk. 
Randomized trials investigating extreme hypofractionation 
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